Research Confirms Daily Aspirin Offers No Long-Term Heart Disease Prevention in Older Adults
Recent research confirms that daily low-dose aspirin provides no long-term cardiovascular protection for healthy older adults and increases bleeding risks, suggesting a reevaluation of its use for primary prevention.
Recent research led by Monash University has reaffirmed earlier findings that daily low-dose aspirin does not provide cardiovascular benefits for healthy older adults and increases the risk of serious bleeding. The study analyzed data from 15,668 individuals, mostly aged 70 and above, who participated in the ASPREE clinical trial and its extended follow-up. Participants who took aspirin showed no overall reduction in cardiovascular events over more than eight years of follow-up, which combined the original trial period and subsequent monitoring. Conversely, these individuals experienced a 17% increase in major hemorrhages compared to those who received a placebo.
The research, published in the European Heart Journal, examined participants who initially had no history of cardiovascular disease, dementia, or physical disabilities affecting independence. The original ASPREE trial, conducted from 2018, involved 4.7 years of initial observation comparing aspirin to placebo, followed by an extension of over four years. During this extended period, authors observed that aspirin users did not gain cardiovascular protection but faced significantly higher risks of bleeding complications.
Professor Rory Wolfe, the lead author, noted that unexpectedly, post-trial results indicated a 17% increase in adverse cardiovascular events among aspirin users. He emphasized that these findings suggest regular aspirin use for primary prevention in healthy older adults should be reconsidered, and individuals should consult their healthcare providers about discontinuing the medication. However, for those with prior cardiovascular events taking aspirin for secondary prevention, continued use may still be appropriate.
The study highlights the importance for older adults and clinicians to carefully evaluate the benefits and risks of daily aspirin therapy, especially given the increased likelihood of bleeding without proven long-term heart health advantages.
Source: https://medicalxpress.com/news/2025-09-aspirin-daily-term-cardiovascular-events.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
CDC Ends its 13-Year Anti-Smoking Campaign Amid Funding Cuts
The CDC is ending its highly successful 'Tips From Former Smokers' anti-smoking campaign after 13 years due to funding cuts, raising concerns about the impact on smoking cessation efforts across the U.S.
Innovative 3D-Printed Tumor Models Enhance Surgical Imaging Techniques
Texas Tech researchers have developed 3D-printed tumor models that replicate human tissue, aiming to refine surgical imaging techniques and improve tumor removal accuracy.
Delays in Hypertension Diagnosis Are Linked to Postponements in Medication Initiation
Delays in diagnosing hypertension can lead to reduced medication initiation and increased cardiovascular risks. A recent study underscores the importance of early detection through electronic health records.
Effective Tools Significantly Increase Pediatricians' Compliance with Peanut Allergy Guidelines
A new study shows that simple, easy-to-use tools can nearly 15-fold increase pediatricians' adherence to guidelines on early peanut allergy prevention, helping to reduce allergy risks in children.